UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 9,928 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 20.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,642 shares of the company's stock after buying an additional 9,928 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.12% of Axsome Therapeutics worth $4,877,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Pitcairn Co. increased its holdings in shares of Axsome Therapeutics by 3.4% during the fourth quarter. Pitcairn Co. now owns 4,562 shares of the company's stock valued at $386,000 after purchasing an additional 148 shares during the period. Meridian Wealth Management LLC boosted its stake in Axsome Therapeutics by 0.7% during the fourth quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company's stock valued at $1,791,000 after buying an additional 150 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in Axsome Therapeutics by 4.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,852 shares of the company's stock valued at $326,000 after buying an additional 162 shares in the last quarter. Arizona State Retirement System boosted its stake in Axsome Therapeutics by 1.8% during the fourth quarter. Arizona State Retirement System now owns 9,054 shares of the company's stock valued at $766,000 after buying an additional 164 shares in the last quarter. Finally, Intrust Bank NA boosted its stake in Axsome Therapeutics by 6.9% during the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company's stock valued at $239,000 after buying an additional 183 shares in the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Truist Financial raised their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Morgan Stanley raised their target price on Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Mizuho raised their target price on Axsome Therapeutics from $212.00 to $216.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. Deutsche Bank Aktiengesellschaft assumed coverage on Axsome Therapeutics in a research note on Tuesday, February 11th. They set a "buy" rating and a $176.00 target price for the company. Finally, Royal Bank of Canada raised their target price on Axsome Therapeutics from $190.00 to $193.00 and gave the company an "outperform" rating in a research note on Tuesday, April 29th. One research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $173.00.

Insiders Place Their Bets

In related news, COO Mark L. Jacobson sold 20,673 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $104.66, for a total value of $2,163,636.18. Following the completion of the sale, the chief operating officer now owns 5,783 shares of the company's stock, valued at approximately $605,248.78. The trade was a 78.14% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Mark Coleman sold 3,000 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $107.49, for a total value of $322,470.00. Following the completion of the sale, the director now directly owns 54,137 shares of the company's stock, valued at approximately $5,819,186.13. The trade was a 5.25% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,423 shares of company stock worth $4,950,619. 22.30% of the stock is currently owned by company insiders.

Axsome Therapeutics Stock Up 1.1%

NASDAQ AXSM traded up $1.25 during trading on Friday, reaching $111.91. 702,024 shares of the company's stock were exchanged, compared to its average volume of 690,077. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The firm has a market capitalization of $5.51 billion, a PE ratio of -18.68 and a beta of 0.47. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The company's fifty day simple moving average is $105.94 and its 200-day simple moving average is $106.67.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.